Trevi Therapeutics receives Nasdaq bid price deficiency notice; has until July 11, 2022 to regain compliance

Trevi Therapeutics, Inc.

Received deficiency letter from Nasdaq on Jan 10, 2022; bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until July 11, 2022) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day compliance period, subject to other standards.
May consider a reverse stock split or other measures to cure; no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.